Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis

We sought to investigate safety of axitinib or sorafenib in renal cell carcinoma (RCC) patients and compare toxicity of these two vascular endothelial growth factor receptor inhibitors. Databases of PubMed and Embase were searched. We included phase II and III prospective trials, as well as retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Fei, Yu, Hao, Xu, Chang-Rong, Chen, Hui-Hui, Bai, Jian-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956256/
https://www.ncbi.nlm.nih.gov/pubmed/29353818
http://dx.doi.org/10.7555/JBR.32.20170080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956256/
https://www.ncbi.nlm.nih.gov/pubmed/29353818
http://dx.doi.org/10.7555/JBR.32.20170080

Ejemplares similares